This randomized, international, multicenter, open-label phase III study investigated the effects of experimental retreatment with subcutaneous bortezomib plus dexamethasone (VD) followed by prolonged bortezomib therapy vs standard VD retreatment in patients with relapsed/refractory multiple myeloma.
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study / Terpos, Evangelos; Gobbi, Marco; Potamianou, Anna; Lahaye, Marjolein; Couturier, Catherine; Cavo, Michele. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 1600-0609. - STAMPA. - 100:1(2018), pp. 10-19. [10.1111/ejh.12937]
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study
GOBBI, MARCO;Cavo, Michele
2018
Abstract
This randomized, international, multicenter, open-label phase III study investigated the effects of experimental retreatment with subcutaneous bortezomib plus dexamethasone (VD) followed by prolonged bortezomib therapy vs standard VD retreatment in patients with relapsed/refractory multiple myeloma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
